Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humansArticle Published on 2022-12-052022-11-15 Journal: The Journal of Experimental Medicine [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibodies antibody Antigen antigenic breadth Breakthrough infection Cell comparable Delta develop dose Effect elicit Frequency Human increase increases in individual Infection memory memory B memory B cell memory B cells memory response Memory responses mRNA mRNA vaccine omicron plasma antibody receive response responses SARS-CoV-2 severe COVID-19 [DOI] 10.1084/jem.20221006 PMC 바로가기
Production of single-cycle infectious SARS-CoV-2 through a trans-complemented repliconArticle Published on 2022-12-012022-11-16 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 치료기술, [키워드] acute respiratory syndrome approach BAC Cell cells clone coated Coronavirus-2 COVID-19 culture supernatant did not produce elicit expression generate IFN immune response infected cell Infection Infectious virus Live attenuated vaccine memory N protein nucleocapsid omicron overexpression plaques platform Production progeny provide Replication replicon rescued resulting RNA robust S protein SARS-CoV-2 single-cycle infectious virus. Strains transient expression transmission electron microscopy type I interferon Vaccine Viral RNA virion virus [DOI] 10.1002/jmv.28057 PMC 바로가기
A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannanArticle Published on 2022-12-012022-11-15 Journal: International journal of biological macromolecules [Category] COVID19(2023년), SARS, 진단, [키워드] ACE2 adjuvant Antibody titer Antigen antigenicity Bacterial cause cellular immunity COVID-19 COVID-19 pandemic cytokine develop domain E. coli effective effective vaccine elicit elicited expected expressed feasibility humoral IFN-γ IL-10 IL-5 IMPROVE Interaction Ligand mannan neutralization neutralizing antibody organs peptide polysaccharide RBD RBD-specific IgG SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 spike protein SARS-CoV-2 vaccine SARS-CoV-2. sera severe respiratory disease Th2-type Toxicity Vaccine Vaccine development viral infection virus [DOI] 10.1016/j.ijbiomac.2022.09.180 PMC 바로가기
Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial재조합 인터페론 무장 융합 단백질 백신(V-01)을 사용한 SARS-CoV-2에 대한 이종 부스팅의 효능: 무작위, 이중 맹검 및 위약 대조 3상 시험Clinical Trial Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] adverse event antibody assigned booster clinical trial common adverse event conducted COVID-19 vaccine COVID-19 vaccines dose double-blind dramatic increase Efficacy elicit eligible fatigue Fever fusion protein groups headache healthy Heterologous heterologous boosting Humoral immunity Identifier Immunity inactivated Inactivated vaccine Inactivated Vaccines Inc injection injection site intention-to-treat principle Malaysia Mild-to-moderate Neutralizing Neutralizing antibodies occurred Older omicron Omicron variant over Pain participant Participants Placebo placebo-controlled primary endpoint Randomized Randomly receive regimen robust Safe SARS-CoV-2 SARS-COV-2 infection second dose Serious Adverse Events subunit Subunit vaccine Subunit vaccine. Surveillance symptomatic SARS-CoV-2 infection the epidemic titre Trial Trial registration V-01 Vaccine vaccine efficacy variant virus-neutralizing antibodies was measured were assessed [DOI] 10.1080/22221751.2022.2088406 PMC 바로가기 [Article Type] Clinical Trial
A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants비강 오미크론 백신 부스터는 새로운 SARS-CoV-2 변이체에 대한 강력한 중화 항체 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] absence adjuvants administration antibody Antibody Response boost booster Bronchoalveolar lavage caused clinical trial composed COVID-19 COVID-19 pandemic current deaths delta variant described disease severity domain dose effective Elevation elicit evidenced FIVE fused human infection human infections humans IgA Immunity immunogen intranasal leads mice MOST mucosal nasal nasal protein vaccine booster Neutralizing activity neutralizing antibody Neutralizing antibody response omicron Omicron variant omicron variant. Protein Receptor binding domain reduce respiratory SARS-CoV-2 SARS-CoV-2 nucleoprotein SARS-CoV-2 spike SARS-CoV-2 transmission SARS-CoV-2 variant severity significantly single dose suggested the antibody response the disease vaccination Vaccine virus infection wild-type [DOI] 10.1080/22221751.2022.2053365 PMC 바로가기 [Article Type] Article
Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primatesArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] accompanied Blood clinical investigation Coverage COVID-19 COVID-19 pandemic COVID-19 vaccine cytokine release Diseases effective effort elicit Gam-COVID-Vac Health heterologous prime-boost IgA antibody IgG immune response Immunity immunization immunogenic immunogenicity Infection intranasal intranasal vaccine. intranasally K18-hACE2 transgenic mice less lung immunopathology mice mononuclear cell Mortality mucosal nasal mucosa neutralizing antibody non-human primate pandemic Peripheral blood Prevent proliferation protective immunity provided revaccination robust SARS-CoV-2 SARS-COV-2 infection SARSCoV-2 serum Sputnik V systemic and local the vaccine Transmission vaccination Vaccination strategy Vaccine vaccine candidate variants of concern virus virus infection virus spread [DOI] 10.1080/22221751.2022.2119169 PMC 바로가기
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal intranasal. Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Perceived feasibility, facilitators and barriers to incorporating point-of-care testing for SARS-CoV-2 into emergency medical services by ambulance service staff: a survey-based approachArticle Published on 2022-11-032022-11-15 Journal: BMJ Open [Category] SARS, 진단, [키워드] Accuracy acquisition ambulance service Analysis approach assessments assistant Care Characteristics clinical decision clinical utility collected COVID-19 criteria current elicit Emergency emergency situation facilitator feasibility feasible Follow-up healthcare services indicated Lateral flow device majority medical service molecular diagnostics Perceived point-of-care qualitative data Qualitative research. rapid SARS-CoV-2 testing required response risk stratification SARS-CoV-2 SARS-CoV-2 test Sensitivity and specificity supported survey to define unlikely while [DOI] 10.1136/bmjopen-2022-064038 PMC 바로가기
A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concernArticle Published on 2022-11-012022-11-15 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] antibodies antigenic chimeric correlated Delta effective elicit flagellin Flagellin adjuvant human ACE2 IgA immunization Infection initial intranasal intranasal immunization Lower lung mucosal mucosal vaccine Mutation nasal neutralizing antibody neutralizing immunity omicron pathology Protein provide RBD reduce SARS-CoV-2 SARS-CoV-2 variant secretory IgA significantly specificity Spread tissue pathology transgenic mice transmission potential Triple-RBD Vaccine vaccine candidate variant Variant of concern. Viral RNA [DOI] 10.1038/s41423-022-00929-3 PMC 바로가기
An additional dose of viral vector COVID-19 vaccine and mRNA COVID-19 vaccine in kidney transplant recipients: A randomized controlled trial (CVIM 4 study)Article Published on 2022-11-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, [키워드] age anti-RBD antibody B cell response BNT162b2 booster Cell-mediated immunity ChAdOx1 ChAdOx1 nCoV-19 comparable Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose elicit group humoral immunization Immunocompromised immunogenicity investigated IQR kidney transplant male median mononuclear cells mRNA mRNA-1273 mRNA-1273. no difference participant Peripheral blood positive Randomized Randomized controlled trial receive recipients response SARS-CoV-2 seroconversion rate significantly statistically T cell Vaccine Viral vector virus neutralization test [DOI] 10.1111/ajt.17151 PMC 바로가기